Cipla signs agreement with Merck for Molnupiravir
Molnupiravir is an investigational oral antiviral drug currently being studied in a Phase 3 trial for the treatment of non-hospitalized patients with confirmed COVID-19
Molnupiravir is an investigational oral antiviral drug currently being studied in a Phase 3 trial for the treatment of non-hospitalized patients with confirmed COVID-19
Apart from the above, it was also decided that Basic Customs Duty on import of COVID-19 vaccines be also exempted with immediate effect for a period of 3 months
These media reports are based on incorrect facts and are without any basis.
Lonza's Ibex Design end-to-end offering will cover the development stages of IMT-009 from development candidates through early clinical studies
Acquisition of A&C expands Aceto’s Western manufacturing footprint
ICICI Securities expects Hemmo to grow its revenue at a CAGR of 30.0% over FY21E-FY23E
Strategic divestment of Ploermel and Edinburgh sites will enable NextPharma to benefit from operational synergies and optimize existing expertise and technologies
Report outlines the wide array of investment opportunities in various segments of India’s healthcare sector
The company had filed a suit in the High Court of Justice, Ghana
Lonza Specialty Ingredients has become LifeClean’s first strategic industrial partner.
Subscribe To Our Newsletter & Stay Updated